Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avadomide + Nivolumab in Advanced Melanoma
NCT03834623Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- May 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avadomide in melanoma, sponsored by Moffitt Cancer Center. Primary endpoint: Objective Response Rate at 52 weeks. Started May 2019; status: completed.
02
Drugs
avadomide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03834623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03834623.